Healthcare / Medical Care FacilitiesTokyo
$158.00
-8.00 (-4.82%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 13%
FCF escenarios
weak_data · normalized FCF $-2.3B · quality 33.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
24/100
D
Piotroski
4/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$5.1B
P/E
N/A
•EV/EBITDA
11.6x
↓ROE
-10.7%
↓Gross Margin
18.5%
↓Debt/Equity
2.61
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+46.5%
FCF CAGR
—
FCF margin
-8.8%
FCF / Net income
2.52x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $26.50B · net income $-925.0M · FCF $-2.33B
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $26.50B | $26.50B | $20.11B | $13.72B | $8.42B |
| Net Income | $-925.0M | $-925.0M | $802.0M | $784.0M | $255.7M |
| EBITDA | $1.88B | $1.88B | $3.15B | $2.00B | $819.0M |
| EPS | -29.12 | -29.12 | 66.87 | 27.29 | 11.01 |
| Gross Margin | 18.5% | 18.5% | 25.6% | 27.3% | 25.0% |
| Operating Margin | 4.2% | 4.2% | 11.3% | 10.5% | 5.8% |
| Net Margin | -3.5% | -3.5% | 4.0% | 5.7% | 3.0% |
| Balance Sheet | |||||
| Debt/Equity | 2.61 | 2.61 | 3.87 | 2.09 | 7.63 |
| Current Ratio | 1.33 | 1.33 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-2.33B | $-2.33B | $-2.94B | $-741.0M | $-78.2M |
| Returns | |||||
| ROE | -10.7% | -10.7% | 15.4% | 14.6% | 29.6% |
| Valuation | |||||
| P/E | — | — | 38.85 | 111.58 | — |
| EV/EBITDA | 11.62 | 11.62 | 30.36 | 48.06 | — |
| P/B | 0.58 | 0.58 | 15.19 | 16.30 | — |
| Growth & Yield | |||||
| Revenue Growth | 31.8% | 31.8% | 46.6% | 62.9% | — |
| EPS Growth | -143.5% | -143.5% | 145.0% | 147.9% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-68.7%
Start / end P/E
n/dx → n/dx
EPS bridge
66.87 → -29.12
Residual
-68.7%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.